Immune checkpoint inhibitor combination therapy

In recent years, Immune checkpoint inhibitors (ICIs) are being approved for the treatment of a wide range of malignancies, and they are one of the most popular immunotherapies for tumours, bringing new hope to patients. However, single-agent ICI therapy has limited efficacy and is prone to drug resistance, and the objective remission rate of ICI alone is only 10-20% in some tumours, therefore, how to improve clinical efficacy is the key point of clinical research associated with immunotherapy. New research has found that the combination of ICIs with differing mechanisms not only improves efficacy, but also prolongs the anti-tumour effect, while an appropriate dosing regimen can effectively balance efficacy and safety. It is proposed to review the mechanism, pharmacokinetics and clinical research progress of ICI combination therapy.